Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | CPT2 | P23786 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464880 | 1.00 | MEN1 (0.73) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Hydrochloric Acid SCHEMBL9465317 | 0.98 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL16238330 | 0.90 | MEN1 (0.73) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL4557816 | 0.89 | MEN1 (0.76) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL6919852 | 0.89 | MEN1 (0.76) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL288495 | 0.88 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL31011113 | 0.88 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL30513874 | 0.88 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Valine SCHEMBL17164660 | 0.87 | MEN1 (0.57) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Alpha-Ketoglutaric Acid SCHEMBL4595160 | 0.87 | MEN1 (0.57) | MEN1KMT2ACYP2C19RECQLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-20250387309-A1 | METHOD FOR THE TREATMENT OF KERATIN FIBRES COMPRISING A PRETREATMENT OR POST-TREATMENT STEP | OREAL (FR) | 2025-12-25 | — | — | US | claimed |
| CN-120048503-A | Preeclampsia risk assessment prediction model based on metabonomics and application thereof | 深圳华大基因股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-120048502-A | Multi-parameter preeclampsia risk assessment prediction model and application thereof | 深圳华大基因股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-4543400-A1 | METHOD FOR THE TREATMENT OF KERATIN FIBRES COMPRISING A PRETREATMENT OR POST-TREATMENT STEP | L'OREAL (FR) | 2025-04-30 | — | — | EP | claimed |
| EP-4537111-A2 | MULTI-OMICS ASSESSMENT | Prognomiq Inc (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119816897-A | Multiple study assessment | 普罗科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119403534-A | Method for treating keratin fibres comprising a pretreatment or post-treatment step | 莱雅公司 | 2025-02-07 | — | — | CN | claimed |
| US-20250003930-A1 | METHOD FOR ANALYZING AMINO ACIDS AND/OR ACYLCARNITINES | SHIMADZU CORPORATION (JP) | 2025-01-02 | — | — | US | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| WO-2002004945-A1 | CLINICAL METHOD FOR THE GENETIC SCREENING OF NEWBORNS USING TANDEM MASS SPECTROMETRY | NEO GEN SCREENING, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| EP-1098630-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | Biomed Research and Technologies, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6166077-A | Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1 | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-12-26 | — | — | US | claimed |
| US-6149924-A | FOR TOPICAL APPLICATION | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2000-11-21 | — | — | US | claimed |
| US-6037373-A | TREATING NERVOUS SYSTEM, CYTOLOGICAL, HORMONAL, GASTROINTESTINAL AND LIVER DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-03-14 | — | — | US | claimed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0909171-A1 | USE OF L-ACETYLCARNITINE, L-ISOVALERYLCARNITINE, L-PROPIONYLCARNITINE FOR INCREASING THE LEVELS OF IGF-1 | Mendes S.R.L. (IT) | 1999-04-21 | — | — | EP | claimed |
| WO-1998001128-A1 | USE OF L-ACETYLCARNITINE, L-ISOVALERYLCARNITINE, L-PROPIONYLCARNITINE FOR INCREASING THE LEVELS OF IGF-1 | MENDES S.R.L. (IT) | 1998-01-15 | — | — | WO | claimed |
| US-5576348-A | Pharmaceutical preparation comprising an acylcarnitine | KURATSUNE HIROHIKO (JP) | 1996-11-19 | — | — | US | claimed |
| EP-0681839-A2 | A pharmaceutical preparation comprising an acylcarnitine | Kuratsune, Hirohiko (JP) | 1995-11-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387309-A1 | METHOD FOR THE TREATMENT OF KERATIN FIBRES COMPRISING A PRETREATMENT OR POST-TREATMENT STEP | PROC, KRT18, VCL | MEN1 4597/4885KMT2A 3415/4885CYP2C19 3314/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | MEN1 3658/4885KMT2A 119/4885CYP2C19 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.